Page last updated: 2024-10-16

adenine and Head and Neck Neoplasms

adenine has been researched along with Head and Neck Neoplasms in 18 studies

Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)

Research Excerpts

ExcerptRelevanceReference
"We tested 17 malignant mucosal melanomas of the head and neck for the thymine (T)-->adenine (A) missense mutation at nucleotide 1796 in the BRAF gene using direct sequencing and a newly developed assay that uses a novel primer extension method (Mutector assay)."3.72Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. ( Begum, S; Cohen, Y; Esche, C; Goldenberg, D; Lavie, O; Rosenbaum, E; Sidransky, D; Westra, WH, 2004)
"Further use in head and neck cancer appears unwarranted."2.68Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. ( Benson, AB; Blough, R; French, S; Kies, M; Kilton, LJ; Lad, T; Mullane, M; Rosen, F; Vokes, EE; Wade, J, 1995)
"The current study tested the anti-HNSCC cell activity by a mTOR kinase inhibitor CZ415."1.48Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells. ( Ding, X; Gao, Y; Li, Q; Xie, J, 2018)
" Furthermore, it also demonstrates the benefits of using preclinical models of chemosensitization to radiotherapy to explore clinically relevant radiation dosing schemes."1.36BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. ( Burrows, F; Lundgren, K; Shores, CG; Wilson, L; Yin, X; Zhang, H, 2010)
"Microsatellite instability was detected in nine cases in both procedures."1.34Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer. ( Canevari, Rde A; dos Santos, RM; Kowalski, LP; Magrin, J; Nishimoto, IN; Poli-Frederico, RC; Rainho, CA; Rogatto, SR; Rosa, FE, 2007)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (11.11)18.2507
2000's6 (33.33)29.6817
2010's8 (44.44)24.3611
2020's2 (11.11)2.80

Authors

AuthorsStudies
Shan, L1
Lu, Y1
Song, Y1
Zhu, X1
Xiang, CC1
Zuo, ED1
Cheng, X1
Jeske, SS1
Brand, M1
Ziebart, A1
Laban, S1
Doescher, J1
Greve, J1
Jackson, EK1
Hoffmann, TK1
Brunner, C1
Schuler, PJ1
Shin, D1
Kim, EH1
Lee, J1
Roh, JL1
Xie, J1
Li, Q1
Ding, X1
Gao, Y1
Soares, AC1
Soares, JC1
Rodrigues, VC1
Follmann, HDM1
Arantes, LMRB1
Carvalho, AC1
Melendez, ME1
Fregnani, JHTG1
Reis, RM1
Carvalho, AL1
Oliveira, ON1
Behbahani, TE1
Rosenthal, EL1
Parker, WB1
Sorscher, EJ1
Khlifi, R1
Kallel, I1
Hammami, B1
Hamza-Chaffai, A1
Rebai, A1
Niu, Y1
Yuan, H1
Shen, M1
Li, H1
Hu, Y1
Chen, N1
Schramm, VL1
Gutierrez, JA1
Cordovano, G1
Basu, I1
Guha, C1
Belbin, TJ1
Evans, GB1
Tyler, PC1
Furneaux, RH1
Yin, X1
Zhang, H1
Lundgren, K1
Wilson, L1
Burrows, F1
Shores, CG1
Sharma, R1
Panda, NK1
Khullar, M1
Cohen, Y2
Xing, M1
Mambo, E1
Guo, Z1
Wu, G1
Trink, B1
Beller, U1
Westra, WH2
Ladenson, PW1
Sidransky, D3
Rosenbaum, E1
Begum, S1
Goldenberg, D1
Esche, C1
Lavie, O1
Boccia, S1
Cadoni, G1
La Torre, G1
Arzani, D1
Volante, M1
Cattel, C1
Gianfagna, F1
Paludetti, G1
Almadori, G1
Ricciardi, G1
Rosa, FE1
dos Santos, RM1
Poli-Frederico, RC1
Canevari, Rde A1
Nishimoto, IN1
Magrin, J1
Rainho, CA1
Kowalski, LP1
Rogatto, SR1
Rosen, F1
Vokes, EE1
Lad, T1
Kies, M1
Wade, J1
Kilton, LJ1
Blough, R1
French, S1
Mullane, M1
Benson, AB1
Leaf, AN1
Neuberg, D1
Schwartz, EL1
Wadler, S1
Ritch, PS1
Dutcher, JP1
Adams, GL1
Fisher, MJ1
Virmani, AK1
Wu, L1
Aplenc, R1
Harper, JC1
Powell, SM1
Rebbeck, TR1
Gazdar, AF1
El-Deiry, WS1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis[NCT00095459]Phase 157 participants (Actual)Interventional2004-11-02Completed
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer[NCT00436215]Phase 255 participants (Actual)Interventional2006-12-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436215)
Timeframe: up to 28 months

InterventionParticipants (Count of Participants)
BAY 43-9006 + Bevacizumab54

Progression-free Survival

Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. (NCT00436215)
Timeframe: up to 28 months

InterventionWeeks (Mean)
BAY 43-9006 + Bevacizumab26

Clinical Response Rate.

Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. (NCT00436215)
Timeframe: patients were followed for a median of 18 weeks (range 1-116 weeks)

Interventionpercentage of participants (Number)
Complete ResponsePartial ResponseProgressive DiseaseStable Disease
BAY 43-9006 + Bevacizumab0192160

Reviews

1 review available for adenine and Head and Neck Neoplasms

ArticleYear
Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.
    Head & neck, 2019, Volume: 41, Issue:6

    Topics: Adenine; Escherichia coli; Head and Neck Neoplasms; Humans; Purine-Nucleoside Phosphorylase; Squamou

2019

Trials

2 trials available for adenine and Head and Neck Neoplasms

ArticleYear
Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study.
    Investigational new drugs, 1995, Volume: 13, Issue:3

    Topics: Adenine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Hum

1995
An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
    Investigational new drugs, 1997, Volume: 15, Issue:2

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head

1997

Other Studies

15 other studies available for adenine and Head and Neck Neoplasms

ArticleYear
Identification of Nine M6A-Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Topics: Adenine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Gene Expression Regulation, Neoplastic; Head a

2022
Adenosine-producing regulatory B cells in head and neck cancer.
    Cancer immunology, immunotherapy : CII, 2020, Volume: 69, Issue:7

    Topics: Adenine; Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Lymphocytes, Regulato

2020
RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Redox biology, 2017, Volume: 13

    Topics: Adenine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2017
Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 46, Issue:2

    Topics: Adenine; Animals; Apoptosis; Autophagy; Beclin-1; Carcinoma, Squamous Cell; Cell Proliferation; Cell

2018
Microfluidic-Based Genosensor To Detect Human Papillomavirus (HPV16) for Head and Neck Cancer.
    ACS applied materials & interfaces, 2018, Oct-31, Volume: 10, Issue:43

    Topics: Adenine; Carcinoma, Squamous Cell; Cell Line, Tumor; Chitosan; Chondroitin Sulfates; DNA, Single-Str

2018
DNA repair gene polymorphisms and risk of head and neck cancer in the Tunisian population.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2014, Volume: 43, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Arginine; Case-Control Studie

2014
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
    The Journal of craniofacial surgery, 2014, Volume: 25, Issue:2

    Topics: 3' Untranslated Regions; Adenine; Adult; Aged; Alcohol Drinking; Carcinoma, Squamous Cell; Case-Cont

2014
Transition state analogues in quorum sensing and SAM recycling.
    Nucleic acids symposium series (2004), 2008, Issue:52

    Topics: Adenine; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors;

2008
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    International journal of cancer, 2010, Mar-01, Volume: 126, Issue:5

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Blotting, Western; Carcinoma, Squ

2010
Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer.
    Oral diseases, 2010, Volume: 16, Issue:7

    Topics: Adenine; Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Carcinogens; Carcinoma, Squamous Cell; CpG

2010
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10

    Topics: Adenine; DNA; Exons; Head and Neck Neoplasms; Humans; Melanocytes; Melanoma; Models, Genetic; Mutage

2004
A case-control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer.
    Journal of cancer research and clinical oncology, 2006, Volume: 132, Issue:7

    Topics: Adenine; Alleles; Arginine; Arylsulfotransferase; Carcinoma, Squamous Cell; Case-Control Studies; Co

2006
Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer.
    Archives of oral biology, 2007, Volume: 52, Issue:8

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Case-Control Studies; Cytosine; Diseas

2007
Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6

    Topics: Adenine; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Alleles; Amino Acid Sequence;

2001